Omega 3 supplements
It is optional for a patient with LOS more than 2 weeks as an
isolated symptom or following resolution of any other COVID
symptoms.
The flow chart (Figure 1) summarizes key
points in relation to treatment, investigations and management of new
onset anosmia during the COVID 19 pandemic.
*Denotes items where consensus was achieved at 60% and not the 70%
threshold, highlighting ongoing uncertainty regarding usage. We
therefore suggest that decisions regarding usage should be made at an
individual patient level, considering the risks in view of comorbidities
and individual patient preferences